title: Market uptake of new antiviral drugs for the treatment of hepatitis C.
abstract: OBJECTIVE
  Peginterferon plus ribavirin is the state-of-the-art antiviral therapy for prevention of serious complications of hepatitis C. Our aim was to compare market uptake of and access to these drugs across Europe.
  
  
  METHODS
  We collected launch and sales data for peginterferons for 21 countries in the WHO European region and compared country-specific sales rates. Additionally, we converted sales figures into patient numbers and related those to country-specific hepatitis C prevalence, taking into account genotype distribution, patient characteristics and practice patterns.
  
  
  RESULTS
  Peginterferon sales rates differed considerably across countries. The earliest, most rapid and highest adoption rates were in EU founder states, followed by EU members that joined after foundation, and EU non-member states. Most new member states showed a marked increase in sales. By the end of 2005, approximately 308,000 patients had been treated with peginterferons in the 21 countries evaluated. The number of patients ever treated ranged from 16% of prevalent cases in France to less than 1% of cases in Romania, Poland, Greece and Russia.
  
  
  CONCLUSIONS
  Peginterferon market uptake and access differed considerably across Europe, suggesting unequal access to optimised therapy. Besides budget restrictions, national surveillance and treatment policies should be considered as reasons for market access variation.
authors.affiliation: Department of Public Health, Medical Decision Making and Health Technology Assessment, UMIT, University for Health Sciences, Medical Informatics and Technology, Hall iT, Austria.
authors.forename: Beate
authors.initials: B
authors.lastname: Lettmeier
authors.forename: Nikolai
authors.initials: N
authors.lastname: Mühlberger
authors.forename: Ruth
authors.initials: R
authors.lastname: Schwarzer
authors.forename: Gaby
authors.initials: G
authors.lastname: Sroczynski
authors.forename: Davene
authors.initials: D
authors.lastname: Wright
authors.forename: Stefan
authors.initials: S
authors.lastname: Zeuzem
authors.forename: Uwe
authors.initials: U
authors.lastname: Siebert
mesh_terms: D000998:Antiviral Agents / Q000191:economics / Q000627:therapeutic use*; D002170:Canada; D018153:Czech Republic; D005062:European Union; D017048:Health Care Costs; D054625:Healthcare Disparities / Q000191:economics*; D006526:Hepatitis C / Q000188:drug therapy* / Q000191:economics; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000191:economics / Q000627:therapeutic use; D008389:Marketing of Health Services / Q000191:economics*; D011092:Polyethylene Glycols / Q000191:economics / Q000627:therapeutic use; D010818:Practice Patterns, Physicians' / Q000191:economics; D011994:Recombinant Proteins; D012254:Ribavirin / Q000191:economics / Q000627:therapeutic use; D014944:World Health Organization
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a